Trials / Not Yet Recruiting
Not Yet RecruitingNCT07520006
Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
An Open-label, Multicenter Phase 1b/2 Study to Evaluate the Safety and Efficacy of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
- Status
- Not Yet Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- Sponsor
- Nurix Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study will evaluate NX-5948 (bexobrutideg) in combination with venetoclax with or without an anti-CD20 antibody (rituximab or obinutuzumab) in second-line or higher (2L+) relapsed/refractory (R/R) or first-line (1L) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Detailed description
Bexobrutideg is an investigational drug designed to target a protein called Bruton tyrosine kinase (BTK), which helps cancer cells grow in certain blood cancers like CLL and SLL. Bexobrutideg is a protein degrader, which means it finds and destroys the BTK in the cell. Venetoclax, rituximab, and obinutuzumab are approved medications that are used to treat CLL/SLL. The study will look at: * How safe bexobrutideg is for patients with CLL or SLL when taken with these other treatments * The effects of bexobrutideg in the body when taken with these other treatments * How well bexobrutideg treats CLL or SLL when taken with these other treatments
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NX-5948 | Administered orally once daily as a capsule |
| DRUG | venetoclax | Administered orally once daily as a tablet per prescribing information |
| DRUG | rituximab | Administered as an intravenous (IV) infusion per prescribing information |
| DRUG | obinutuzumab | Administered as an IV infusion per prescribing information |
Timeline
- Start date
- 2026-05-01
- Primary completion
- 2033-05-01
- Completion
- 2033-05-01
- First posted
- 2026-04-09
- Last updated
- 2026-04-13
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07520006. Inclusion in this directory is not an endorsement.